Hagino Teppei, Saeki Hidehisa, Fujimoto Eita, Kanda Naoko
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Department of Dermatology, Nippon Medical School, Tokyo, Japan.
J Dermatol. 2025 Apr;52(4):634-641. doi: 10.1111/1346-8138.17665. Epub 2025 Feb 7.
Real-world evidence on the long-term effectiveness of deucravacitinib, a selective tyrosine kinase 2 inhibitor for psoriasis, remains limited, particularly in patients with different histories of systemic treatments. We evaluated the 52-week effectiveness of deucravacitinib in patients with psoriasis, stratified by a history of apremilast or biologic usage. This prospective, single-center study included 110 patients with moderate-to-severe psoriasis who received daily deucravacitinib (6 mg). Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores during the treatment were analyzed in subgroups stratified by a history of apremilast or biologic usage. Deucravacitinib decreased PASI and DLQI scores for 52 weeks in psoriasis patients, both with and without prior apremilast or biologic usage. The percent reductions from baseline PASI or DLQI at week 52 were similar in apremilast-experienced patients (92% or 77.9%) and apremilast-naive patients (88.3% or 81.6%), respectively. The achievement rates of PASI 100 or absolute PASI ≤1 at week 52 in apremilast-experienced patients (30.8% or 61.5%) were slightly higher than those in apremilast-naive patients (20.5% or 46.2%). The percent reductions from baseline PASI or DLQI at week 52 in biologic-naive patients (91.6 or 82.8%) were slightly higher than those in biologic-experienced patients (57.6% or 63.6%), respectively. The achievement rates of PASI 75, 100 or absolute PASI ≤1 at week 52 in biologic-naive patients (84.4%, 24.4%, or 53.3%) were slightly higher than those in biologic-experienced patients (57.1%, 14.3%, or 28.6%), respectively. Deucravacitinib generated sustained 52-week effectiveness in diverse patient subgroups, supporting its role as a universal treatment for psoriasis.
对于用于治疗银屑病的选择性酪氨酸激酶2抑制剂氘可来昔替尼的长期有效性，真实世界证据仍然有限，尤其是在有不同全身治疗史的患者中。我们评估了氘可来昔替尼在银屑病患者中的52周有效性，并根据阿普米拉斯或生物制剂使用史进行分层。这项前瞻性单中心研究纳入了110例中重度银屑病患者，他们每日服用氘可来昔替尼（6毫克）。在根据阿普米拉斯或生物制剂使用史分层的亚组中，分析了治疗期间的银屑病面积和严重程度指数（PASI）以及皮肤病生活质量指数（DLQI）评分。无论有无阿普米拉斯或生物制剂使用史，氘可来昔替尼均能在52周内降低银屑病患者的PASI和DLQI评分。在有阿普米拉斯使用经验的患者（分别为92%或77.9%）和无阿普米拉斯使用经验的患者（分别为88.3%或81.6%）中，第52周时PASI或DLQI较基线的降低百分比相似。在有阿普米拉斯使用经验的患者中，第52周时达到PASI 100或绝对PASI≤1的达标率（分别为30.8%或61.5%）略高于无阿普米拉斯使用经验的患者（分别为20.5%或46.2%）。在未使用过生物制剂的患者中，第52周时PASI或DLQI较基线的降低百分比（分别为91.6或82.8%）略高于有生物制剂使用经验的患者（分别为57.6%或63.6%）。在未使用过生物制剂的患者中，第52周时达到PASI 75、PASI 100或绝对PASI≤1的达标率（分别为84.4%、24.4%或53.3%）略高于有生物制剂使用经验的患者（分别为57.1%、14.3%或28.6%）。氘可来昔替尼在不同患者亚组中产生了持续52周的有效性，支持其作为银屑病通用治疗方法的作用。
